Hospices Civils De Lyon — Sponsor Intelligence | 39 EU Trials

Filter these 39 trials by condition, phase, country and more.

Open in Search →

39 Registered trials

20 Recruiting

11 Completed trials

1 Countries active

70 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase III: 9 Phase II/III: 3 Phase II: 16 Phase I/II: 3 Phase IV: 5 Phase I (Other): 1 Phase I (FiH): 1 Other: 1

Oversight events:

3 temporary halts 1 urgent safety measure 1 unexpected event 1 corrective measure across 4 trials

View oversight register →

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Gestational trophoblastic tumour 1 Obesity 1 Prostate cancer metastatic 1 Stem cell transplant 1 Anaplastic thyroid cancer 1 Asthma 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Neuroendocrine carcinoma metastatic 1 Peritoneal mesothelioma malignant 1 Sepsis 1 Arrhythmogenic right ventricular dysplasia 1 Limbal stem cell deficiency 1

Top IMPs

DOMVANALIMAB 2 NINTEDANIB 2 SODIUM CHLORIDE 2 ZIMBERELIMAB 2 (1-(111C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE 1 [18F]-ALTANSERIN 1 [18F]CPFPX 1 1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PYRIDINYL]PIPERAZINE 1 4-FLUORO-N-[2-[4-(2-METHOXYPHENYL)PIPERAZIN-1-YL]ETHYL]-N-PYRIDIN-2-YLBENZAMIDE 1 ABACAVIR, LAMIVUDINE 1 BEFIRADOL (18F) 1 BOTULINUM TOXIN TYPE A 1

All trials

39 total

PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic co… Not authorised

2024-519922-19-00 Phase II 1 country DOMVANALIMAB; ZIMBERELIMAB
New therapeutic approach to Toxic Epidermal Necrolysis (TEN) using anti-CD38+ antibodies in the active phase of the disease – Phase I/II stu… Pending

2024-512164-63-00 Phase I/II 1 country
Efficacy of prophylactic levetiracetam for improving functional outcome in the acute phase of intracerebral haemorrhage: a randomised, doub… Pending

2024-515663-59-00 Phase III 1 country LEVETIRACETAM
ADRESS : Efficacy of the Alpha 2 agonist dexmedetomidine for sympathetic Deactivation in REfractory Septic Shock: a randomized, controlled t… Pending

2025-524122-18-00 Phase III 1 country DEXMEDETOMIDINE
Impact of epilepsy on the brainstem adenosine pathway and its relation with arousal and respiratory reactivity BRAVE Pending

2025-524511-36-00 Phase II 1 country [18F]CPFPX
Diving into the noradrenergic system : Role of the alpha2C-adrenergic receptors NA2C-TEP-IRM Pending

2025-524602-15-00 Phase II 1 country 1-[[(3S)-2,3-DIHYDRO-1,4-BENZODIOXIN-3-YL]METHYL]-4-[3-((11C)METHOXYMETHYL)-2-PY…
A PET-MRI study of serotoninergic brainstem pathway in patients with Dravet Syndrome - DRAPETONINE Recruiting

2025-524199-40-00 Phase II 1 country 4-FLUORO-N-[2-[4-(2-METHOXYPHENYL)PIPERAZIN-1-YL]ETHYL]-N-PYRIDIN-2-YLBENZAMIDE
Randomised, controlled phase II proof-of-concept trial to assess the efficacy of abaCavIr/lamivudine treatment on the interferon signature i… Recruiting

2023-508611-22-00 Phase II 1 country ABACAVIR, LAMIVUDINE
BACLOFEN FOR IMPROVING BENZODIAZEPINE TITRATION IN BENZODIAZEPINE DEPENDENCE. BABET Recruiting

2022-502307-30-00 Phase II/III 1 country
CLEARTOX: Development of an innovative haemodialysis method to improve dialytic clearance of protein-bound uraemic toxins Recruiting

2023-510406-41-00 Phase II 1 country SODIUM CHLORIDE; TRIGLYCERIDES, MEDIUM CHAIN, SOYA OIL
ReaLuP : Study on Re-treatment with Radiopharmaceutical Drug [177Lu]Lu-PSMA in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting

2024-512043-22-00 Phase II 1 country GOZETOTIDE; LUTETIUM (177LU) VIPIVOTIDE TETRAXETAN
BLOCKADE OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN PATIENTS WITH ARVD.BRAVE Recruiting

2023-505048-20-00 Phase II 1 country SPIRONOLACTONE
Involvement of the serotonergic system in the control of impulsivity in Tourette disorder : ARITEP Recruiting

2023-506370-13-00 Phase II 1 country [18F]-ALTANSERIN
HydroxyChloroquine as steroid-sparing Agent in Extra-pulmonary SARcoidosis. A multicenter, prospective, placebo-controlled, randomized trial… Recruiting

2022-502155-65-00 Phase III 1 country HYDROXYCHLOROQUINE SULFATE
Evaluation of EXL01 a new Live Biotherapeutic Product to prevent recurrence of Clostridioides difficile infection in high-risk patients. LIV… Recruiting

2023-506232-32-00 Phase I/II 1 country EXL01
OBEVIDOS “Treatment of vitamin D deficit in obese children and adolescents: an open label randomized controlled study comparing the efficacy… Recruiting

2023-507089-18-00 Phase III 1 country COLECALCIFEROL
Human recombinant interferon gamma in the treatment of ventilator-acquired pneumonia in ICU patients. IGNORANT study Recruiting

2022-502229-16-00 Phase III 1 country RECOMBINANT HUMAN INTERFERON GAMMA 1B; SODIUM CHLORIDE
A RANDOMIZED DOUBLE BLIND, PLACEBO-CONTROLLED NATIONAL MULTICENTER PHASE 3 TRIAL TO EVALUATE THE EFFICACY OF AZATHIOPRINE FOR THE PREVENTION… Recruiting

2022-500520-30-00 Phase III 1 country
Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Recruiting

2024-515275-35-00 Phase II/III 1 country FILGRASTIM; GLUCOSE MONOHYDRATE
Exploration of the pathophysiology of cluster headache (AVF) in PET-MRI using [18F]F13640 Recruiting

2024-513873-36-00 Phase II 1 country BEFIRADOL (18F)
Postoperative analgesic effect of orally administrated nefopam after a total knee arthroplasty: a randomized controlled trial (NefPO) Recruiting

2024-513796-40-00 1 country MORPHINE HYDROCHLORIDE; MORPHINE SULFATE; NEFOPAM HYDROCHLORIDE
Efficiency of everolimus for the treatment of kidney transplanted patients presenting a rejection Recruiting

2024-513814-37-00 Phase IV 1 country EVEROLIMUS
Cultured Autologous Oral Mucosa Epithelial sheet for the Treatment of Bilateral Limbal Stem Cell Deficiency FEMJA for « Feuillet Epithélial … Recruiting

2024-513939-24-00 Phase I (FiH) 1 country
LOADEX: PILOT AND PHASE 2 STUDY OF THE EFFICACY OF A TREATMENT PROTOCOL WITH DEXAMETHASONE IMPLANT LOADING DOSE IN PATIENTS WITH DIABETIC MA… Recruiting

2024-514362-39-00 Phase II 1 country DEXAMETHASONE

Showing 1–24 of 39 trials

← All sponsors A–Z